Diagnostics News and Research

RSS

New FEI software package increases electron microscope throughput, ease-of-use

FEI Company ,a leading scientific instrumentation company providing electron microscopy systems for nanoscale applications across many industries, released today a set of software applications that increase the throughput and ease-of-use of its electron microscopes for biological research. The four software packages make electron microscopes more useful for life science researchers involved in structural, cellular and tissue biology as they build the full solution from sample to biological answer.

3 Aug 2010

IRIS International closes AlliedPath acquisition

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has closed the acquisition of AlliedPath, Inc., a private, early stage high complexity, CLIA-certified laboratory focused on oncology and molecular diagnostics.

2 Aug 2010

Almac's solutions to support biopharma companies by adopting biomarker strategies

Almac today announced the launch of Biomarkers for biopharma a range of solutions specifically designed to meet the needs of the biopharma industry.Almac's solutions are to support biopharma companies in adopting biomarker strategies to enable them to better understand their drug, improve their drug's success rate, improve the drug's value and ultimately maximise their drug's potential.

2 Aug 2010

Cell-of-origin for prostate cancer identified

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

31 Jul 2010

FDA announces approval of vaccines for 2010-2011 US influenza season

The U.S. Food and Drug Administration announced today that it has approved vaccines for the 2010-2011 influenza season in the United States.

31 Jul 2010

Pathwork Diagnostics enters into research collaboration with Novartis

Pathwork Diagnostics Inc., a molecular diagnostics company focused on oncology, today announced that it has entered into a research collaboration with Novartis. The parties intend to discover clinically meaningful biomarker signatures that can serve as the basis for diagnostics across a range of cancer types. Under the terms of the agreement, both parties have rights to develop and commercialize the diagnostic products. Financial terms were not disclosed.

31 Jul 2010

Idaho Technology signs licensing agreement with E. I. du Pont de Nemours

Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.

31 Jul 2010

Epigenetic changes to DNA in breast cancers linked with environmental risk factors, tumor size: Study

Researchers from Brown University and the University of California San Francisco have found that epigenetic changes to DNA in breast cancers are related to environmental risk factors and tumor size, providing a window into the severity of the disease. The study is published in today's edition of PLoS Genetics. The researchers found that epigenetic profiles of tumors had a direct association with diet, alcohol, and tumor size.

31 Jul 2010

Partners in ENIAC project announce details of multinational/multidisciplinary program

The partners in a new publicly-funded European research project today announced details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC project aims to achieve substantial advances in state-of-the-art medical 3D-imaging platforms by focusing on the diagnosis and therapy of serious diseases of the central nervous system and brain.

30 Jul 2010

Gen-Probe second-quarter 2010 product sales up 14%

Gen-Probe Incorporated today reported financial results for the second quarter of 2010, highlighted by 14% growth in product sales, 15% growth in total revenues, and 16% growth in non-GAAP earnings per share.

30 Jul 2010

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

30 Jul 2010

BioCurex’s RECAF blood test potential to monitor cancer recurrence, treatment

BioCurex Inc. today announced that the International Society of Oncology and Biomarkers Congress Scientific Committee has accepted BioCurex's presentation on the RECAF blood test potential to monitor cancer recurrence and treatment. The meeting will be held Sept. 3-8, 2010 in Munich, Germany and is broadly attended by scientists, physicians and biotechnology companies involved in cancer diagnostics.

30 Jul 2010

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

Covidien plc today reported results for the third quarter of fiscal 2010 (April - June 2010). Third-quarter net sales of $2.56 billion increased 2% from the $2.52 billion reported a year ago, with foreign exchange rate movement having no impact on the quarterly sales growth rate.

29 Jul 2010

Ortho Kinematics: 23 patients enrolled in KineGraph VMA clinical study

Ortho Kinematics, a privately held spine diagnostics company focused on revolutionizing spine motion analysis, announced today that it has begun a multi-site clinical study of the KineGraph VMA™, and that the initial 23 patients have been enrolled. The study will help determine which types of patients are best evaluated with KineGraph VMA testing. The KineGraph VMA is designed to provide functional diagnostic information to spine surgeons to be used in conjunction with MRI and plain X-rays.

29 Jul 2010

BD third-quarter revenues increase 3.2% to $1.878 billion

BD, a leading global medical technology company, today reported quarterly revenues of $1.878 billion for the third fiscal quarter ended June 30, 2010, representing an increase of 3.2 percent from the prior-year period, or 3.9 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 29 Jul 2010

Clarient second-quarter net revenue increases 21% to $28.7 million

Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the second quarter ended June 30, 2010. Second quarter 2010 net revenue was $28.7 million, a 21 percent increase over the $23.7 million net revenue in the 2009 second quarter and a sequential increase of nearly eight percent over the $26.6 million in the first quarter of 2010.

29 Jul 2010

Quest Diagnostics' Fragile X Syndrome test receives New York State health department approval

An accurate, faster testing option to identify female carriers and other patients with genetic abnormalities that cause Fragile X Syndrome is now available to physicians in all fifty states with the recent approval in New York. Fragile X is the leading cause of inherited mental retardation and the most common known single gene cause of autism.

From Quest Diagnostics 29 Jul 2010

VaxGen completes merger transaction with diaDexus

VaxGen, Inc. announced today the completion of its merger transaction with diaDexus, Inc., a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease.

29 Jul 2010

Vitro Diagnostics, Mokshagundam Biotechnologies enter contract to develop stem cell-derived food

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it has entered into a contract with Mokshagundam Biotechnologies, a private research organization established to develop alternative meat sources, to develop cell culture medium for use in exploration of alternative food sources derived from stem cells.

28 Jul 2010

Roche to present diagnostics testing solutions at 2010 Clinical Lab Expo

Roche is featuring a diverse portfolio of diagnostics testing solutions for healthcare professionals in booth #2808 at the AACC/CSCC 2010 Clinical Lab Expo here, July 27-29 – and it's giving them a unique way to see firsthand where their own "dream lab" might take them.

From Roche Sequencing and Life Science 28 Jul 2010